Ozempic Lawsuits

Legal Help for Patients Suffering Vision Loss or Gastrointestinal Injuries from Ozempic

Ozempic® (semaglutide) was developed to help patients manage type 2 diabetes and, more recently, has been widely prescribed for weight loss. Manufactured by Novo Nordisk, Ozempic is part of a class of drugs known as GLP-1 receptor agonists, which includes Wegovy® and Mounjaro®.

While these medications have gained massive popularity, serious and potentially permanent injuries have been reported — including vision loss caused by NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) and severe gastrointestinal conditions such as gastroparesis, intestinal blockage, and persistent vomiting.

Our firm represents patients across the United States who have suffered these complications and are holding Novo Nordisk accountable for failing to adequately warn consumers and healthcare providers.

Reported Injuries Linked to Ozempic

Patients who used Ozempic for diabetes or weight loss have reported two major categories of injury:

1. Vision Loss (NAION)

• NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) is a form of optic nerve damage that causes sudden, painless, and often permanent vision loss.

• Studies suggest that GLP-1 drugs like Ozempic may reduce blood flow to the optic nerve, leading to nerve damage and irreversible blindness.

• Symptoms include blurred or dimmed vision, partial field loss, or sudden blindness in one or both eyes.

2. Gastrointestinal Conditions

• Gastroparesis (paralyzed stomach), where the stomach muscles stop moving food properly, leading to nausea, vomiting, and severe bloating

• Intestinal obstruction or blockage requiring hospitalization or surgery

• Severe abdominal pain and dehydration

• Persistent vomiting or inability to tolerate food

• Gallbladder issues or pancreatitis

Many patients were not adequately warned of these risks and were told side effects would be temporary — only to experience life-changing, long-term harm.

Why Patients Are Filing Ozempic Lawsuits

Lawsuits allege that Novo Nordisk:

• Knew or should have known about the risks of NAION and serious gastrointestinal injuries

• Failed to include adequate warnings on product labeling

• Downplayed reports of long-term and disabling side effects in marketing and public communications

• Promoted Ozempic and similar drugs for weight loss in ways that encouraged widespread off-label use

Patients claim they would not have taken the medication — or would have monitored symptoms more closely — if properly informed of the risks.

Current Status of the Ozempic Litigation

Ozempic and similar GLP-1 drug lawsuits (including Wegovy and Mounjaro) are in the early stages of national litigation. In early 2024, the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated these cases into Multidistrict Litigation (MDL No. 3094) in the Eastern District of Pennsylvania.

Hundreds of plaintiffs are now pursuing claims related to severe gastrointestinal injuries and vision loss, and additional filings continue to rise as more patients come forward.